論文

国際誌
2023年

Immune Checkpoint Inhibitors for Nasopharyngeal Carcinoma in a Real-world Setting in Japan.

In vivo (Athens, Greece)
  • Tomomi Manako
  • Ryuji Yasumatsu
  • Takafumi Nakano
  • Mioko Matsuo
  • Toranoshin Takeuchi
  • Masahiko Taura
  • Akihiro Tamae
  • Moriyasu Yamauchi
  • Muneyuki Masuda
  • Kenichi Taguchi
  • Takashi Nakagawa
  • 全て表示

37
2
開始ページ
747
終了ページ
755
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.21873/invivo.13137

BACKGROUND/AIM: The advent of immune checkpoint inhibitor (ICI) treatment has transformed the treatment of recurrent or metastatic head and neck cancer; however, nasopharyngeal carcinoma (NPC) has not been included in major phase III trials. The clinical outcomes of ICI for NPC in real-world practice remain to be fully elucidated. PATIENTS AND METHODS: We retrospectively reviewed 23 patients with recurrent or metastatic NPC treated with nivolumab or pembrolizumab at 6 institutions from April 2017 to July 2021 and investigated the correlation of clinicopathological factors and immune-related adverse events with the effects of ICI therapy and the prognosis. RESULTS: The objective response rate was 39.1% and the disease control rate was 78.3%. The median progression-free survival was 16.8 months and overall survival has not been reached. As with other treatment procedures, the efficacy and the prognosis tended to be better in EBER-positive cases than in EBER-negative cases. The rate of significant immune-related adverse events that necessitated discontinuation of treatment was only 4.3%. CONCLUSION: ICI monotherapy (e.g., nivolumab and pembrolizumab) was effective and tolerable for NPC in a real-world setting.

リンク情報
DOI
https://doi.org/10.21873/invivo.13137
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/36881083
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026669
ID情報
  • DOI : 10.21873/invivo.13137
  • PubMed ID : 36881083
  • PubMed Central 記事ID : PMC10026669

エクスポート
BibTeX RIS